Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Expects Avastin Colon Cancer Data Ahead Of Schedule In 2009

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised timeline for the C-08 trial does not change Genentech’s assessment of probability of success.

You may also be interested in...



Roche To Partner With Two European Biotechs On Oncology Candidate

Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.

Roche To Partner With Two European Biotechs On Oncology Candidate

Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.

Avastin Passes Tox Test In Colon Cancer

Drug and control arms in C-08 study of Genentech drug turn out the same.

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel